Dysfunction of HDAC6 closely associated with disease outcome and targeting HDAC6 as anti‐cancer therapeutics has been extensively investigated with some potential drugs being advanced in clinical trials.[13] Nevertheless, the relevance of HDAC6 to the pathogenesis of AD and its potential as a drug target for AD is still unclear and needs in‐detail investigation for developing therapeutics. Here, HDAC6 is linked to cancer.